SBIR/STTR Research Award

Identification of Compounds to Induce Suspended Animation or Hypometabolism

Award identifier bc80cd043640a45e496321c70f127e6ad9d86e38970a1487919c8dbb2cbe053aAwarding agency Department of Defense · Office for Chemical and Biological Defense

Award amount

$69,861

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Office for Chemical and Biological Defense
Recipient company
Neuralstem, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
RNZ2EFVDQDW3
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Suspended or reduced animation of brain and heart tissues during battle-field injury or during critical-care trauma may result in a significant protection from organ damage, systemic shock, and pain and may provide a prolonged window of opportunity fortreatment. Suspended or reduced animation of brain and heart tissues may be achieved by a complete suspension or suppression of neural activities (hypometabolism) in the CNS. The primary objective of this Phase I feasibility research is to identifyhypometabolic effects of serum and brain tissue extracts from hibernating Arctic ground squirrels (AGS) on human brain neurons and glia. Potential effects of AGS extracts on several different aspects of neuronal activity/metabolism will be quantified inorder to establish robust assays for high throughput screening of small molecule libraries as well as for purification of hibernation factor(s). Identification of the agents with hypometabolic efficacy on human brain cells in vitro would then lead tofurther testing of those agents for potential therapeutic values in animal models of various human disesaes, including traumatic brain injury, spinal injury, and ischemic stroke. Hypometabolic factors or small molecules with hypometabolic effects may beeffective in minimizing tissue damage during/after stroke, traumatic brain injury, spinal injury, and major surgeries. Effective agents will be further developed as commercial therapeutics for these and other indications. They may also have immediateapplication to sustaining viability and thus enhancing commercial potential of Neuralstem's cell lines during transport.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

5 SBIR/STTR records share this UEI (1999–2018). Reported award amounts total $1,790,127. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.